Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications
Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies.
Journal: Lancet (London, England)
Published: February 27, 2026
Three-dimensional imaging for facial vitiligo: Results from a phase 2 randomized controlled trial investigating upadacitinib in patients with vitiligo.
Journal: The Journal of investigative dermatology
Published: August 25, 2025
Psychometric properties of the Vitiligo Noticeability Scale using data from a phase II randomized study of upadacitinib in adults with nonsegmental vitiligo.
Journal: The British journal of dermatology
Published: March 03, 2025
Psychometric Properties and Meaningful Change Thresholds of the Vitiligo Area Scoring Index.
Journal: JAMA dermatology
Published: October 30, 2024
Improvements in moderate-to-severe hidradenitis suppurativa with upadacitinib: Results from a phase 2, randomized, placebo-controlled study.
Journal: Journal of the American Academy of Dermatology
Published: June 10, 2024
Response to Reynolds et al's "Guidelines of care for the management of acne vulgaris".
Journal: Journal of the American Academy of Dermatology
Published: May 09, 2024
Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study.
Journal: EClinicalMedicine
Published: January 12, 2024
Comparing clinical acne vulgaris severity to adolescent and parent perceptions of acne severity and impact on quality of life.
Journal: Pediatric dermatology
Published: May 29, 2020
Vulvar Squamous Cell Carcinoma in a Patient With Vulvar Lichen Sclerosus.
Journal: JAMA dermatology
Published: May 09, 2019
Pyoderma gangrenosum of the vulva treated with mycophenolate mofetil and infliximab.
Journal: Dermatologic therapy
Published: February 26, 2019
Hyperkalemia in women with acne exposed to oral spironolactone: A retrospective study from the RADAR (Research on Adverse Drug Events and Reports) program.
Journal: International journal of women's dermatology
Published: February 15, 2019
Last Updated: 09/26/2026